206 related articles for article (PubMed ID: 25315362)
41. [Ketamine administration in case of severe, therapy resistant depressed patient, case report].
Morvai S; Nagy AI; Bálint-Szöllősi A; Móré EC; Berecz R; Frecska E
Ideggyogy Sz; 2016 Nov; 69(11-12):421-425. PubMed ID: 29733561
[TBL] [Abstract][Full Text] [Related]
42. Antidepressant response and subthreshold bipolarity in "unipolar" major depressive disorder: implications for practice and drug research.
Rihmer Z; Dome P; Gonda X
J Clin Psychopharmacol; 2013 Aug; 33(4):449-52. PubMed ID: 23775059
[No Abstract] [Full Text] [Related]
43. Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
Fawcett J; Rush AJ; Vukelich J; Diaz SH; Dunklee L; Romo P; Yarns BC; Escalona R
Am J Psychiatry; 2016 Feb; 173(2):107-11. PubMed ID: 26844792
[No Abstract] [Full Text] [Related]
44. Ketamine for treatment-resistant bipolar depression-need for more data!
Singh B; Vande Voort JL; Kung S
Bipolar Disord; 2021 Nov; 23(7):728-729. PubMed ID: 34549861
[No Abstract] [Full Text] [Related]
45. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review.
Mathai DS; Meyer MJ; Storch EA; Kosten TR
J Affect Disord; 2020 Mar; 264():123-129. PubMed ID: 32056741
[TBL] [Abstract][Full Text] [Related]
46. A word to the wise about ketamine.
Schatzberg AF
Am J Psychiatry; 2014 Mar; 171(3):262-4. PubMed ID: 24585328
[No Abstract] [Full Text] [Related]
47. Role of copper and ketamine in major depressive disorder - an update.
Słupski J; Słupska A; Szałach ŁP; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Wiglusz MS; Cubała WJ
Psychiatr Danub; 2019 Sep; 31(Suppl 3):520-523. PubMed ID: 31488784
[TBL] [Abstract][Full Text] [Related]
48. Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence.
Averill LA; Fouda S; Murrough JW; Abdallah CG
Adv Pharmacol; 2020; 89():163-194. PubMed ID: 32616206
[TBL] [Abstract][Full Text] [Related]
49. Progress in treatment-resistant bipolar depression using repeated ketamine infusions.
van den Brink W; van Amsterdam J
Bipolar Disord; 2023 Sep; 25(6):517-518. PubMed ID: 37311591
[No Abstract] [Full Text] [Related]
50. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
51. Ketamine - Undrawn Lines between Medical and Recreational Use - Implications for Clinical Practice.
Jonovska S; Sugnet T; Šendula-Jengić V
Psychiatr Danub; 2021; 33(Suppl 4):1113-1117. PubMed ID: 35354177
[TBL] [Abstract][Full Text] [Related]
52. Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh DA; Niciu MJ; Ionescu DF; Nolan NM; Richards EM; Brutsche NE; Guevara S; Zarate CA
J Affect Disord; 2014 Apr; 159():56-61. PubMed ID: 24679390
[TBL] [Abstract][Full Text] [Related]
53. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.
Abdallah CG; Fasula M; Kelmendi B; Sanacora G; Ostroff R
J ECT; 2012 Sep; 28(3):157-61. PubMed ID: 22847373
[TBL] [Abstract][Full Text] [Related]
54. Repeated infusions of ketamine for treatment-resistant bipolar depression in real-world practice.
Zhou Y; Chen X; Ning Y
Bipolar Disord; 2023 Sep; 25(6):515-516. PubMed ID: 37545011
[No Abstract] [Full Text] [Related]
55. Electroconvulsive therapy is a standard treatment; ketamine is not (yet).
Kellner CH; Greenberg RM; Ahle GM; Liebman LS
Am J Psychiatry; 2014 Jul; 171(7):796. PubMed ID: 24980176
[No Abstract] [Full Text] [Related]
56. Ketamine: Leading us into the future for development of antidepressants.
Carreno FR; Lodge DJ; Frazer A
Behav Brain Res; 2020 Apr; 383():112532. PubMed ID: 32023492
[TBL] [Abstract][Full Text] [Related]
57. Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.
Zavaliangos-Petropulu A; Al-Sharif NB; Taraku B; Leaver AM; Sahib AK; Espinoza RT; Narr KL
Biol Psychiatry Cogn Neurosci Neuroimaging; 2023 Apr; 8(4):361-386. PubMed ID: 36775711
[TBL] [Abstract][Full Text] [Related]
58. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects.
Le TT; Di Vincenzo JD; Teopiz KM; Lee Y; Cha DS; Lui LMW; Rodrigues NB; Ho RC; Cao B; Lin K; Nasri F; Gill H; Lipsitz O; Subramaniapillai M; Mansur RB; Rosenblat JD; McIntyre RS
Psychiatry Res; 2021 Dec; 306():114231. PubMed ID: 34798487
[TBL] [Abstract][Full Text] [Related]
59. Time-Course of Depression Improvement With Ketamine Adjunction in Electroconvulsive Therapy.
Romeo B; Choucha W; Fossati P; Rotge JY
J ECT; 2016 Jun; 32(2):80-1. PubMed ID: 26766630
[No Abstract] [Full Text] [Related]
60. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.
Lundin NB; Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Brutsche NE; Machado-Vieira R; Zarate CA
Pharmacopsychiatry; 2014 Jul; 47(4-5):141-4. PubMed ID: 24955551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
